enGene Therapeutics Inc.
ENGN
Last
$1.73
Day
-2.8%
1y
-80.0%
5y
-81.9%
52w
-85.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
1.87
EMA 50
1.94
EMA 200
3.78
20d high
-14.4%
5y high
-96.2%
5y range
1th
Positions held
Your positionsENGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$1.95
Stop
$1.64
Stop distance
5.2%
Target vs last
+12.7%
Fundamentals
| Market cap | $119.29M | Enterprise value | -$113.76M | Trailing P/E | — | Forward P/E | -1.22 |
| PEG | — | Price / book | 0.52 | Beta | -0.29 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -60.5% | ROA | -32.0% | Debt / equity | 0.14 |
| Current ratio | 10.21 | Free cash flow | -$60.85M | Analyst recommendation | none | Mean target | $3.29 |
| 52w high | $12.25 | 52w low | $1.40 |
Quarterly
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$32.5M | -$30.2M | -$29.8M | -$37.9M | -$29.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$34.0M | -$32.0M | -$31.2M | -$39.5M | -$29.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$117M | -$55.1M | -$99.9M | -$24.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$123M | -$62.3M | -$26.1M | -$19.4M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-09-01 · enGene to Participate in Upcoming Investor Conferences
2026-08-13 · enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
2026-07-15 · Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
Price (daily)
Full chart · RSI · MACD · patternsENGN · daily-13.2% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin